TrialJournal of cancer research and clinical oncology2024

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.

Dayang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.